SAN DIEGO, Nov. 15, 2011 /PRNewswire/ -- Biocept, Inc. today reported that its scientists and academic collaborators will present three posters at the 34th annual San Antonio Breast Cancer Symposium (SABCS) taking place in San Antonio, TX December 6-10, 2011. The poster presentations describe data generated on Biocept's proprietary OncoCEE™ (Oncology Cell Enrichment and Extraction) platform, which enables efficient CTC capture and detection, as well as biomarker analysis on the captured CTCs (e.g., HER2, ER and PR status), as demonstrated in the posters. These data represent findings from several studies involving blood and bone marrow samples from patients with breast cancer.
Farideh Bischoff, PhD, Vice President of Translational Research at Biocept, said, "Our posters present data that demonstrates our ability to detect estrogen receptor in CTCs, which can be clinically useful in patients for whom a biopsy is not feasible, and validation for HER2 FISH analysis performed on CTCs that are cytokeratin (CK) positive and, more importantly, CK negative. Additionally, a collaborative poster presented with colleagues from the MD Anderson Cancer Center compares the detection of HER2 gene amplification in CTCs in blood and disseminated tumor cells (DTCs) in bone marrow in patients with non-metastatic breast cancer. We think that Biocept's OncoCEE-BR™ assay for breast cancer, used for these studies, is ideal for the immunocytochemical, cytogenetic and molecular characterization of CTCs and DTCs, may be an important and clinically significant tool."
Additional details for the SABCS presentations are as follows:
Wednesday, Dec 7, 5:00 – 7:00 PM (PI-07-13)
Efficiency of a Laboratory Developed HER2 FISH Test on Circulating Tumor Cells
Friday, Dec 9, 7:00 AM – 9:00 AM (P 4-06-03)
Detection of HER2 gene amplification in circulating tumor cells and dissemin
|SOURCE Biocept, Inc.|
Copyright©2010 PR Newswire.
All rights reserved